obesity

A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.  The SPAC Deal: Gelesis announced a SPAC merger with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). The deal values the company at a pro forma market...

9 Meters Biopharma Inc (NASDAQ: NMTR) has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP) from Lobesity LLC. GIP is a hormone whose concentration increases significantly with overeating, leading to...

A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug developers at Regeneron will use its VelocImmune technology, which generates antibodies from humanized mice, to find drugs...

Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain overweight people and should be used in conjunction with diet and exercise, Novo...

Since 1975, global obesity levels have tripled. The most recent figures from the World Health Organization (WHO) found that over 1.9 billion adults were overweight and over 650 million were obese. These figures continue to rise despite attempts by governments and organizations to reverse the trends...

Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg. The company will launch the trial in the second...

Move over, American Eagle Outfitters (NYSE: AEO). There’s a new contender in clothing retail, and it’s gonna be big. Supersized, even. McDonald’s Corporation (NYSE: MCD) will launch its limited-edition apparel and merchandise line July 26 in honor of Global Delivery Day. “To...

Shares of EnteroMedics Inc (NASDAQ: ETRM), a nano-cap medical device company that uses neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, fell more than 28 percent early Tuesday morning, after soaring 30 percent the day before. The large sell-off in...

SunTrust said it hasn't changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)'s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:...

Here's some irony for you: while the U.S. public faces an obesity epidemic, health-related stocks are looking lean and mean these days. Growing concerns over the costs to America in terms of productivity, healthcare costs and even an enjoyable lifestyle from obesity and other issues is indeed...

Obesity drug manufacturer VIVUS (NASDAQ: VVUS) slumped 22 percent in early trade Tuesday, as the company reported a net loss of $40.40 million or $0.40 per share in the third quarter. Analysts and investors had anticipated losses of $0.32 for the recently approved Qsymia makers. VIVUS announced...